全基因组关联研究识别HLA-DR变异增加HBV相关慢加急性肝衰竭风险
在399例HBV相关慢加急性肝衰竭(ACLF)与401例无症状HBV携带者中进行全基因组关联研究,并在四个独立病例对照集中重复验证(共901例ACLF和1686例无症状携带者)。在合计1300例ACLF和2087例无症状携带者中,发现HLA II类区域rs3129859与HBV相关ACLF相关(合并P显性=2.64×10-20,OR=1.83),HLA-DRB1*12:02为最显著易感等位基因(p=3.94×10-6,OR=2.05)。
要点
- HLA II类区域rs3129859与HBV相关ACLF易感相关,合并P显性=2.64×10-20,OR=1.83。
- HLA-DRB1*12:02为与ACLF相关的最显著易感HLA等位基因,p=3.94×10-6,OR=2.05。
- 风险等位基因rs3129859*C与凝血酶原时间延长、腹水进展加快及28天死亡率升高相关。
核心结论
- 全基因组关联研究识别HLA-DR为HBV相关ACLF易感性的主要位点。
- 研究结果强调HLA II类限制性CD4+ T细胞通路在HBV相关ACLF免疫发病机制中的重要性。
研究设计与样本
- 全基因组关联研究,初始在399例HBV相关ACLF(病例)与401例未经抗病毒治疗的无症状HBV携带者(对照)中进行。
- 初始发现后在四个独立病例对照集中重复验证,共901例ACLF和1686例无症状HBV携带者。
- 合计分析1300例ACLF和2087例无症状HBV携带者,并分析风险变异对ACLF临床特征的作用。
主要发现
- 在1300例ACLF和2087例无症状HBV携带者中,识别出人类白细胞抗原(HLA)II类区域(染色体6p21.32)的rs3129859与HBV相关ACLF相关(合并P显性=2.64×10-20,OR=1.83)。
- 分析识别HLA-DRB1*12:02为与ACLF相关的最显著易感HLA等位基因(p=3.94×10-6,OR=2.05)。
- rs3129859的关联在ACLF亚组中稳健:合并肝硬化的ACLF(p=1.36×10-16)、无肝硬化的ACLF(p=1.52×10-7)、低复制期患者(p=6.36×10-11,OR=2.29)及HBV e抗原阴性慢性乙型肝炎期患者(p=1.51×10-14,OR=1.86)。
- ACLF患者临床特征分析显示,风险等位基因rs3129859*C与凝血酶原时间延长、腹水进展加快及28天死亡率升高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Acute-on-chronic liver failure (ACLF) is an extreme condition after severe acute exacerbation of chronic hepatitis B; however, the underlying genetic factors involved in its onset and progression are currently unclear. DESIGN: We carried out a genome-wide association study among 399 HBV-related ACLFs (cases) and 401 asymptomatic HBV carriers (AsCs, as controls) without antiviral treatment. The initial findings were replicated in four independent case-control sets (a total of 901 ACLFs and 1686 AsCs). The roles of risk variants on clinical traits of ACLF were also analysed. RESULTS: Among 1300 ACLFs and 2087 AsCs, we identified rs3129859 at human leucocyte antigen (HLA) class II region (chromosome 6p21.32) associated with HBV-related ACLF (combined P dominant =2.64×10-20, OR=1.83). Analysis identified HLA-DRB1*12:02 as the top susceptible HLA allele associated with ACLF (p=3.94×10-6, OR=2.05). The association of rs3129859 was robust in ACLF subgroups (ACLFs with liver cirrhosis, p=1.36×10-16; ACLFs without liver cirrhosis, p=1.52×10-7), and patients at low-replicative phase (p=6.36×10-11, OR=2.29) or HBV e antigen-negative chronic hepatitis B phase (p=1.51×10-14, OR=1.86). Clinical traits analysis in patients with ACLF showed that the risky rs3129859*C allele was also associated with prolonged prothrombin time, faster progression to ascites development and higher 28-day mortality. CONCLUSIONS: Our genome-wide association study identified HLA-DR as the major locus for susceptibility to HBV-related ACLF. Our findings highlight the importance of HLA class II restricted CD4+ T-cell pathway on the immunopathogenesis of HBV-related ACLF.
引用
- Tan W, Xia J, Dan Y, et al. Genome-wide association study identifies HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure. Gut. 2017. PMID: 28130311. doi:10.1136/gutjnl-2016-313035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。